A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
Crossref DOI link: https://doi.org/10.1007/s12282-015-0593-z
Published Online: 2015-02-06
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shiba, Eiichi
Yamashita, Hiroko
Kurebayashi, Junichi
Noguchi, Shinzaburo
Iwase, Hirotaka
Ohashi, Yasuo
Sasai, Kiyofumi
Fujimoto, Tsukasa
License valid from 2015-02-06